How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Free Thyroxine Index

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

CR by the the international workshop on CLL (iwCLL) and the Lugano Response Criteria for Non-Hodgkin's Lymphoma. duration of response (DOR) [ Time Frame: Up to 3 years ] The interval from the first documentation of confirmed CR or PR (by IRC) to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria excluding lymphocytosis alone. progression free survival (PFS) rate [ Time Frame: From (...) % decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions. overall survival (OS) rate [ Time Frame: From the start of treatment until the date of death from any cause, whichever comes first, up to 100 months ] The interval from the start of study treatment to death from any cause. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2017 Clinical Trials

182. Pembrolizumab in Elderly Patients With Advanced Lung Cancer

Criteria (irRC). However, for determination of overall response rate (ORR) and progression-free survival (PFS), the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be used. Adverse events will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment with MK-3475 will continue until two years of therapy have been administered, documented disease progression (...) cancer. Impact on functional assessments measured with Barthel scale [ Time Frame: From the first dose until the last dose of treatment (12 months later) ] To evaluate the impact on functional geriatric assessments of patients older than 70 years with advanced non-small cell lung cancer. Progression-free Survival (PFS) [ Time Frame: From the inclusion date in the study until first progression (at 9 months approximately) documented according to RECIST criteria ] To describe Progression-free Survival

2017 Clinical Trials

183. Effect of Dietary Selenium Deficiency on the Cell Apoptosis and the Level of Thyroid Hormones in Chicken. (Abstract)

(containing 0.033 mg of Se/kg). Fifteen chickens were killed in each group on days 30, 60, and 90, respectively. Then, serum and testes were collected and used in the detection of experimental index. Results indicated that GSH-Px activity and Bcl-2 mRNA level in the testes and thyroidal triiodothyronine (T3) and free triiodothyronine (FT3) levels in serum by dietary Se deficiency were significantly decreased compared to the corresponding control groups. Se deficiency-treated group showed a significant (...) increase in MDA concent, TUNEL-positive cells, and mRNA level of Bax, Caspase3, and p53 in the testes and thyroidal thyroxine (T4), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) levels in serum. Histopathologically, Se deficiency caused impairments in the testes. These results suggested that dietary Se deficiency exerts significant harmful effects on male reproductive organ and that the intrinsic and extrinsic pathways and the upstream regulators such as p53, Bax, and Bcl-2 were all

2017 Biological trace element research Controlled trial quality: uncertain

184. Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

with nivolumab To assess progression free survival and overall survival when RE is combined with nivolumab To assess the quality of life using the FACT-HEP score and EORTC QLQ-C30 To assess the safety and tolerability of the combination of RE and nivolumab Exploratory objectives To evaluate the relationship between tumor biopsy PD-L1 expression and response to treatment with Y90 radioembolization in combination with nivolumab To assess relationship between blood lymphocyte (e.g., T cell) activation (...) of Nivolumab ] Duration of Response [ Time Frame: From date of first assessment of CR or PR until the first date that progressive disease or death is documented, up to 2 years ] Time to Progression [ Time Frame: From date of first dose with Y90 RE until the first date that progressive disease is documented, up to 12 weeks after last dose of Nivolumab ] Progression Free Survival [ Time Frame: From date of first dose with Y90 RE until tumour progression, or death from any cause, up to 12 weeks after last

2017 Clinical Trials

185. Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

as levels of serum total testosterone and free testosterone. Secondary efficacy measurements included changes from baseline in the number of 'yes' answers on the Androgen Deficiency in the Aging Male questionnaire (ADAM), levels of serum total cholesterol, HDL-C, LDL-C, triglyceride, perceived stress scale (PSS-10), all domain scores of the International Index of Erectile Function (IIEF), as well as changes in body composition. Condition or disease Intervention/treatment Phase Hypogonadism Drug: TFG (...) index ≥ 45 kg/m2, HBsAg (hepatitis B surface antigen) positive, prostate specific antigen (PSA) ≥ 4.0 ng/ml, cardiac failure, or a history of alcoholism or substance abuse. Patients who had taken PDE5 inhibitors, TRT, anti-androgen, statins, fibrates, niacin, steroid, fish oil, colestin, fiber-based laxatives, phytosterol margarines, anti-diabetics, anti-platelet, thyroxine, diuretics, or beta-blockers were also excluded. Contacts and Locations Go to Information from the National Library of Medicine

2017 Clinical Trials

186. Theophylline Treatment for Pseudohypoparathyroidism

cirrhosis and acute hepatitis (AST or ALT >3x upper limit of normal) Congestive heart failure Current cigarette use or alcohol abuse Pregnancy or intention to become pregnant during the next year Untreated hypothyroidism (defined as free thyroxine below the lower limit of normal) Active peptic ulcer disease Current use of medications known to effect theophylline levels History of hypersensitivity to theophylline or other medication components History of Major Depressive Disorder in the past 2 years (...) in children and young adults with PHP. Theophylline is a non-selective PDE inhibitor that is generically available and has a long history of use in pediatric patients, making it an ideal drug for re-purposing in youth with PHP. Furthermore, the pharmacokinetics of theophylline are well understood and serum drug levels are easily measured. The investigators primary outcome is change in body mass index. Secondary outcome measures include change in glucose tolerance and HRT dose. Anticipating a 10% dropout

2017 Clinical Trials

187. The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure

the relationship between brown adipose tissue (BAT) volume/activity, white adipose tissue (WAT) partitioning and basal metabolic rate (BMR) in hyperthyroid patients transitioning to euthyroidism via antithyroid drugs. To compare euthyroid outcomes (BAT, WAT, BMR, body composition, body weight and insulin resistance) achieved by hypothalamus-pituitary-thyroid (HPT) set point vs. normal ranges of plasma free thyroxine 4 (FT4) and throxine stimulating hormone (TSH). Condition or disease Intervention/treatment (...) for: (AHRQ) related information: Groups and Cohorts Go to Intervention Details: Drug: carbimazole (CMZ) or thiamazole (TMZ) CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range. Outcome Measures Go to Primary Outcome Measures : Thyroid function test (serum free thyroxine (FT4) and serum thyroid stimulating hormone (TSH). [ Time Frame: 6 months of treatment with an anti-thyroid drug ] This observation supports the concept of a unique set point in FT4 and TSH for any

2017 Clinical Trials

188. Prevention of Diabetes in Overweight/Obese Preadolescent Children

, and triglycerides), glucose, insulin, and hemoglobin A1c, cytokines (e.g. tumor necrosis factor alpha and IL-6) adipokines (e.g leptin and adiponectin), hepatokines (fetuin-A and fibroblast growth factor-21), liver enzymes (alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase), C-reactive protein, thyroid hormones (thyroid stimulating hormone, triiodothyronine and free thyroxine), urea, bilirubin and uric acid Other Outcome Measures: Confounding variable: puberty stage [ Time (...) aerobic activities, and strength exercises Outcome Measures Go to Primary Outcome Measures : Insulin resistance [ Time Frame: Baseline and at the end of the 22 weeks of intervention ] The Homeostasis model assessment index will be calculated as fasting insulin concentration (microU/mL) x fasting glucose concentration (mmol/L)/22.5. microRNA expression in circulating exosomes and in blood peripheral mononuclear cells [ Time Frame: Baseline and at the end of the 22 weeks of intervention ] The expression

2017 Clinical Trials

189. Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

[ Time Frame: Approximately every 12 weeks and/or re-staging through study completion (up to 2 years) ] Secondary Outcome Measures : Treatment-related adverse events [ Time Frame: Continuous, at minimum every 3 weeks until study completion (up to 2 years) ] Progression free survival (PFS) of pembrolizumab in combination with lanreotide depot in subjects with GEP-NETs. [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause (whichever (...) within ≤ 7 days prior to the first dose of study drug, for women of childbearing potential only. Female subjects agree to use two birth control methods, be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study drug. Male subjects agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug. Exclusion Criteria: Tumor mitotic rate >20/10 hpf and/or Ki67 index

2017 Clinical Trials

190. Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients

completion, an average of 4 months ] measurement of serum levels of free triiodothyronine (fT3) - unit of measure: pg/mL, normal range: 1.7-3.7; measurement of serum levels of free thyroxine (fT4) - unit of measure: pg/mL, normal range: 7-15 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you (...) , the following data were collected: probiotic assumption, sex, age, hypothyroidism aetiology, LT4 formulation dose and brand, body mass index (BMI), body surface area (BSA), systolic blood pressure, diastolic blood pressure, heart rate, TSH, fT4, fT3 and any possible LT4 posology adjustment. All the clinical data have been further databased. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 80 participants Allocation: Randomized

2017 Clinical Trials

191. A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Prevalent hemodialysis patients, elevated thyrotropin level, normal free thyroxine level. Exclusion Criteria: Hyperthyroidism, active treatment with thyroid hormone replacement, prior (...) : Baseline and 12 weeks ] Change in serum soluble CD40 ligand level Body mass index [ Time Frame: Baseline and 12 weeks ] Change in body mass index Biceps skinfold [ Time Frame: Baseline and 12 weeks ] Change in biceps skinfold Triceps skinfold [ Time Frame: Baseline and 12 weeks ] Change in triceps skinfold Mid-arm circumference [ Time Frame: Baseline and 12 weeks ] Change in mid-arm circumference Mid-arm muscle circumference [ Time Frame: Baseline and 12 weeks ] Change in mid-arm muscle circumference

2017 Clinical Trials

192. A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

retardation, or any other disease/procedure/accident/intervention which, according to the screening clinician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years. Presents with any of the following lab abnormalities: Thyroid stimulating hormone (TSH) outside of the normal limits and clinically significant as determined by the investigator. Free thyroxine (T4) levels may be measured if TSH level is high. Subject (...) one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline. Body mass index between 18-35 kg/m2. Concurrent psychotherapy will be allowed if the type (e.g

2017 Clinical Trials

193. Establishing Global Reference Values for Human Milk

delivery. Other data collected on mothers and infants, including maternal and infant nutrient intake and status, morbidity, milk volume, and infant development, will inform interpretation and support application of the results. While the priority is to develop RVs for MN, other analyses will include human milk oligosaccharides (HMOs) and proteins, and free amino acids (FAA) in infant plasma. Thus, with the samples obtained the investigators will perform (a) laboratory analyses of milk, plasma and urine (...) and infants will be assessed in blood and urine Milk volume [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Measurements of usual daily milk volume using deuterated water or, in Denmark, 24 hour infant weighing Maternal and infant iodine status [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Urinary iodine; thyroid stimulating hormone, thyroglobulin and thyroxine in dried blood spots Milk iodine [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Milk iodine Maternal

2017 Clinical Trials

194. Stimulation of thyroid function by hCG during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. (Abstract)

gonadotropin, thyrotropin (TSH), and free thyroxine (FT4) were measured in 5435 pregnant women participating in a prospective cohort. The association of hCG with thyroid disease entities, and the association of known risk factors with thyroidal response to hCG stimulation were studied using multivariable linear regression models.Higher hCG concentrations were associated with a higher risk of subclinical and overt hyperthyroidism. Lower hCG concentrations were associated with a higher risk (...) Stimulation of thyroid function by hCG during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. Thyroid autoimmunity is a major risk factor for gestational thyroid disease, and recently various other risk factors have been identified, including maternal age, body mass index (BMI) and parity. Human chorionic gonadotropin (hCG) is an important determinant of gestational thyroid function, yet it is unknown to what extent differences in hCG concentration affect

2017 Thyroid

195. Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). Full Text available with Trip Pro

Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). Subclinical hypothyroidism (SCH) is a common condition in elderly people, defined as elevated serum thyroid-stimulating hormone (TSH) with normal circulating free thyroxine (fT4). Evidence is lacking about the effect of thyroid hormone treatment. We describe the protocol of a large randomised controlled trial (RCT) of Levothyroxine treatment (...) ), fatal and non-fatal cardiovascular events, handgrip strength, executive cognitive function (Letter Digit Coding Test), basic and instrumental activities of daily living, haemoglobin, blood pressure, weight, body mass index and waist circumference. Patients are monitored for specific adverse events of interest including incident atrial fibrillation, heart failure and bone fracture.This large multicentre RCT of levothyroxine treatment of subclinical hypothyroidism is powered to detect clinically

2017 BMC Endocrine Disorders Controlled trial quality: predicted high

196. Identifying Subpopulations Vulnerable to the Thyroid-Blocking Effects of Perchlorate and Thiocyanate. Full Text available with Trip Pro

and Nutrition Examination Survey evaluating the exposure to perchlorate, thiocyanate, and nitrate in 3151 participants aged 12 to 80.Blood serum free thyroxine (FT4) as both a continuous and categorical variable. We also assessed blood serum thyroid stimulating hormone.Controlling for serum cotinine, body mass index, total daily energy consumption, race/ethnicity, and poverty-to-income ratio, for each log unit increase in perchlorate, FT4 decreased by 0.03 ng/dL in both the general population (P = 0.004

2017 Journal of Clinical Endocrinology and Metabolism

197. Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. Full Text available with Trip Pro

; p.I131T) was identified in an 8-year-old boy with moderate hypothyroidism (TSH: 2.61 mIU/L, Normal: 0.27 to 4.2; free thyroxine: 9.52 pmol/L, Normal: 10.9 to 25.7) who was overweight (body mass index: 20.4 kg/m2, p91) but had normal stature (122 cm; -0.58 standard deviation). His mother, two brothers, and grandmother were heterozygous for the mutation with isolated hyperthyrotropinemia (TSH: 4.3 to 8 mIU/L). The I131T mutation, in TRHR intracellular loop 2, decreases TRH affinity and increases

2017 Journal of Clinical Endocrinology and Metabolism

198. Management of Thyroid Cancer

Differentiated thyroid cancer* EBRT External beam radiotherapy EORTC European Organisation for Research and Treatment of Cancer ETA European Thyroid Association FACS Fluorescent activated cell sorter FNMTC Familial non-medullary thyroid cancer FDG Fluoro-deoxy-glucose FKGL Flesch-Kincaid Grade Level FMTC Familial medullary thyroid cancer FNAB Fine-needle aspiration biopsy FNAC Fine-needle aspiration cytology FRAX Fracture Risk Assessment Tool FTC Follicular thyroid cancer* FT4 free thyroxine FVPTC follicular

2014 British Association of Endocrine and Thyroid Surgeons

200. Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version

–56 y; P < .05) in family members diagnosed by predictive genetic testing.[ ] Nonetheless, the lag time between the diagnosis of MEN1 in an and the diagnosis of MEN1 in family members can be significant, leading to increased morbidity and mortality.[ ] This was demonstrated in a Dutch MEN1 Study Group analysis, which showed that 10% to 38% of non-index cases already had an MEN1-related manifestation at diagnosis; 4% of these individuals died of an MEN1-related cause that developed during or before (...) (18F-FDG PET-CT) identified those NETs with an increased malignant potential; the FDG avidity correlated with a Ki-67 index.[ ] Tumor size does seem to influence patient survival, with patients with smaller tumors having increased survival after resection.[ ] While more-extensive surgical approaches (e.g., pancreatoduodenectomy) have been associated with higher cure rates and improved overall survival,[ - ] they also have higher rates of postoperative complications and long-term morbidity

2016 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>